ClinicalTrials.gg
Active, not recruitingNCT05703178Updated Oct 29, 2026

Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

A Phase 3 interventional study of Online Pain Coping Skills Training and Education in Breast Cancer, Arthralgia and Pain, Chronic, sponsored by Northwestern University. Active, not recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Northwestern University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies in Breast Neoplasms by Northwestern University — 4 open to participants now, 6 under way, 1 of them phase 3. Breast Neoplasms · Northwestern University.

Planned enrollment
Largest of 50
452 · median 31
Started
2023
with 3 others
Phase 3
3 of 64
none open now
Registered
57th of 64
by date

Among the 64 studies in Breast Neoplasms by Northwestern University, this one has the largest planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 3, and was the 57th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 64 studies in Breast Neoplasms by Northwestern University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by Northwestern University, or all of them as a file.
02

Study summary

The main goal of this clinical trial is to test benefits of completing online pain coping skills training program in women who have been diagnosed with stage I-III breast cancer, who have completed their primary cancer treatment, who are taking an AI medication, and who have arthralgia. Arthralgia is a type of joint, bone, and muscle pain that is a common side effect of AI medications. The main questions it aims to answer are:

  1. Whether online pain coping skills training reduces the severity of pain and the interference it causes in women's daily lives.
  2. Whether online pain coping skills training improves emotional distress, quality of life, and adherence to AI medications.
  3. Whether benefits of online pain coping skills training are at least partially caused by women's increased confidence that they can manage their pain and a reduction in unhelpful thinking patterns about pain.
  4. Whether online pain coping skills training improves effects of AI medications on sleep problems and symptoms of menopause like hot flashes and night sweats.

Participants can complete all parts of the study at home. They will:

  1. Complete four sets of questionnaires throughout the study, which will take about 9 to 10 months.
  2. Attend 3 meetings in the first month of the study, all of which can be held via a video conference.
  3. Use an electronic pill bottle to track their use of their AI medication.
  4. Be randomized (like flipping a coin) to one of two study arms: They will either receive education about AIs and arthralgia or they will receive this education along with access to an online pain coping skills training program.

Research will compare the education group to the education plus online pain coping skills training group to see if online pain coping skills training has the benefits mentioned above.

03

Conditions studied

  • Breast Cancer
  • Arthralgia
  • Pain, Chronic

Keywords

  • Breast Cancer, Arthralgia, Aromatase Inhibitors, Pain Coping Skills Training, Cognitive Behavioral Therapy, Non-Pharmacologic Pain Treatments
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female sex
  • Aged 18 years old or older
  • Diagnosed with Stage 0-III hormone receptor positive breast cancer
  • Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy)
  • Currently taking AI therapy (letrozole, exemestane, or anastrozole)
  • Reporting musculoskeletal pain that developed or worsened since starting AI therapy
  • Reporting at least 15 days of pain in the past 30 days
  • A worst pain rating of 4 or more on an 11 point (0-10) numerical rating scale in the past week
  • Based on known factors affecting their prognosis, patient is likely to be able to complete the study protocol
  • performance status of 0-2
  • English proficient
  • If participants are taking analgesics, they must be on a stable analgesic regimen for at least 14 days prior to enrollment and should not have planned upward dose titration of their analgesics during the study period. (Note: Patients may elect to decrease their analgesic use during the study as per discussion with their provider. Unexpected dose adjustments including dose escalations due to unforeseen clinical need is allowed. Cannabis taken for pain relief would qualify as an analgesic)
  • Comfortable using a tablet computer, a computer, or a smartphone to access online training

Exclusion criteria

Exclusion Criteria:

  • Evidence of disease
  • Other active cancer (with the exception of non-melanoma skin cancer)
  • Completed chemotherapy or radiation therapy less than four weeks prior to enrollment (these treatments can cause temporary exacerbation of musculoskeletal symptoms that typically resolve spontaneously)
  • Completed surgery less than 8 weeks prior to enrollment (because surgery can cause temporary post-surgical pain that typically resolves in this period of time); minor surgeries may be allowed more recently than 8 weeks at the discretion of the study team
  • Have diagnosed or suspected condition that would interfere with or completion of study activities (e.g., significant impairment in cognition or uncorrected hearing/vision)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
452 participants (estimated)

Study arms

  • Experimental
    Education + Online Pain Coping Skill Training

    Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects. They will also be given access to an online pain coping skills training program and asked to complete it at home over 8 to 10 weeks. This interactive, web-based program teaches cognitive and behavioral skills that research has shown can reduce pain and pain-related interference with daily activities. The program includes eight sessions that participants will complete at a rate of about 1 per week. Each session takes 35-45 minutes. Participants will be shown how to use the program and can contact the study team if they have any problems with it. Participants who do not have a device capable of accessing the program will be loaned a tablet computer for the study.

    Behavioral: Online Pain Coping Skills Training · Other: Education

  • Active comparator
    Education

    Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.

    Other: Education

Interventions

  • BehavioralOnline Pain Coping Skills Training

    The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.

  • OtherEducation

    Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.

06

What researchers measure

Primary outcomes

  1. Change in Brief Pain Inventory pain severity subscale

    We will calculate the mean of the four items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate more severe pain. Analyses will examine group differences in change in pain severity.

    Time frame: Change in BPI pain severity from baseline to 10-14 weeks post-baseline (Follow up 1)

  2. Change in Brief Pain Inventory pain interference subscale

    We will calculate the mean of the seven items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate greater interference. Analyses will examine group differences in change in pain interference.

    Time frame: Change in BPI pain interference from baseline to 10-14 weeks post-baseline (Follow up 1)

Secondary outcomes

  1. Change in Brief Pain Inventory pain severity subscale

    We will calculate the mean of the four items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate more severe pain. Analyses will examine group differences in change in pain severity.

    Time frame: Change in BPI pain severity score from baseline to 22-26 weeks post-baseline (Follow up 2)

  2. Change in Brief Pain Inventory pain severity subscale

    We will calculate the mean of the four items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate more severe pain. Analyses will examine group differences in change in pain severity.

    Time frame: Change in BPI pain severity score from baseline to 34-38 weeks post-baseline (Follow up 3)

  3. Change in Brief Pain Inventory pain interference subscale

    We will calculate the mean of the seven items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate greater interference. Analyses will examine group differences in change in pain interference.

    Time frame: Change in BPI pain severity score from baseline to 22-26 weeks post-baseline (Follow up 2)

  4. Change in Brief Pain Inventory pain interference subscale

    We will calculate the mean of the seven items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate greater interference. Analyses will examine group differences in change in pain interference.

    Time frame: Change in BPI pain severity score from baseline to 34-38 weeks post-baseline (Follow up 3)

  5. Change in Hospital Anxiety and Depression Scale

    We will reverse score items as necessary, and then sum responses to the measure's 14 items to yield a total score ranging from 0 to 42; higher scores indicate greater emotional distress. Analyses will examine group differences in change in emotional distress.

    Time frame: Change in HADS score from baseline to 10-14 weeks post-baseline (Follow up 1)

  6. Change in Hospital Anxiety and Depression Scale

    We will reverse score items as necessary, and then sum responses to the measure's 14 items to yield a total score ranging from 0 to 42; higher scores indicate greater emotional distress. Analyses will examine group differences in change in emotional distress.

    Time frame: Change in HADS score from baseline to 22-26 weeks post-baseline (Follow up 2)

  7. Change in Hospital Anxiety and Depression Scale

    We will reverse score items as necessary, and then sum responses to the measure's 14 items to yield a total score ranging from 0 to 42; higher scores indicate greater emotional distress. Analyses will examine group differences in change in emotional distress.

    Time frame: Change in HADS score from baseline to 34-38 weeks post-baseline (Follow up 3)

  8. Change in Functional Assessment of Cancer Therapy-Lymphedema (FACT-B)

    We will use the total score for the FACT-B, normalizing scores according to standard scoring methods to yield a score from 0-100; higher scores indicate greater Health-Related Quality of Life (HRQoL). Analyses will examine group differences in change in HRQoL.

    Time frame: Change in FACT-B total score from baseline to 10-14 weeks post-baseline (Follow up 1)

  9. Change in Functional Assessment of Cancer Therapy-Lymphedema (FACT-B)

    We will use the total score for the FACT-B, normalizing scores according to standard scoring methods to yield a score from 0-100; higher scores indicate greater Health-Related Quality of Life (HRQoL). Analyses will examine group differences in change in HRQoL.

    Time frame: Change in FACT-B total score from baseline to 22-26 weeks post-baseline (Follow up 2)

  10. Change in Functional Assessment of Cancer Therapy-Lymphedema (FACT-B)

    We will use the total score for the FACT-B, normalizing scores according to standard scoring methods to yield a score from 0-100; higher scores indicate greater Health-Related Quality of Life (HRQoL). Analyses will examine group differences in change in HRQoL.

    Time frame: Change in FACT-B total score from baseline to 34-38 weeks post-baseline (Follow up 3)

  11. Change in Medication Adherence Rating Scale

    Using standard scoring instructions, we will first rescore each of the 10 items on this scale to indicate adherence (=1) or non-adherence (=0), then sum them to yield a score from 0 to 10; higher scores indicate better self-reported medication adherence. Analyses will examine group differences in change in adherence.

    Time frame: Change in MARS scores from baseline to 10-14 weeks post-baseline (Follow up 1)

  12. Change in Medication Adherence Rating Scale

    Using standard scoring instructions, we will first rescore each of the 10 items on this scale to indicate adherence (=1) or non-adherence (=0), then sum them to yield a score from 0 to 10; higher scores indicate better self-reported medication adherence. Analyses will examine group differences in change in adherence.

    Time frame: Change in MARS scores from baseline to 22-26 weeks post-baseline (Follow up 2)

  13. Change in Medication Adherence Rating Scale

    Using standard scoring instructions, we will first rescore each of the 10 items on this scale to indicate adherence (=1) or non-adherence (=0), then sum them to yield a score from 0 to 10; higher scores indicate better self-reported medication adherence. Analyses will examine group differences in change in adherence.

    Time frame: Change in MARS scores from baseline to 34-38 weeks post-baseline (Follow up 3)

  14. Change in Use event data from electronic pill bottle (Medication Event Monitoring System or MEMS Cap pill bottles)

    We will use data from these pill bottles, gathered daily throughout the study, to compute an adherence score (percentage of days on which the prescribed dose of medication was taken) and evaluate group differences in change in adherence from baseline to each of the post-intervention assessments.

    Time frame: Change in MEMS-recorded adherence from baseline to 10-14 weeks post-baseline (Follow up 1)

  15. Probability of optimal adherence using event data from electronic pill bottle (Medication Event Monitoring System or MEMS Cap pill bottles)

    We will use data from these pill bottles, gathered daily throughout the study, to compute an adherence score (percentage of days on which the prescribed dose of medication was taken) and evaluate group differences in probability of optimal adherence, using a dichotomous variable using a cutoff of \<80% to identify sub-optimal adherence (where 80% or greater adherence is optimal).

    Time frame: Probability of MEMS-recorded optimal adherence from baseline to 10-14 weeks post-baseline (Follow up 3)

Other outcomes

  1. Change in Chronic Pain Self-Efficacy Scale Pain Management Subscale

    Using standard scoring procedures, we will calculate the mean of responses to this subscale's 5 items to yield a total score ranging from 10-100, where higher scores indicate greater self-efficacy for managing chronic pain. Analyses will examine change in pain self-efficacy.

    Time frame: Change in Self-efficacy for pain management from baseline to 10-14 weeks post-baseline (Follow up 1)

  2. Change in Chronic Pain Self-Efficacy Scale Pain Management Subscale

    Using standard scoring procedures, we will calculate the mean of responses to this subscale's 5 items to yield a total score ranging from 10-100, where higher scores indicate greater self-efficacy for managing chronic pain. Analyses will examine change in pain self-efficacy.

    Time frame: Change in Self-efficacy for pain management from baseline to 22-26 weeks post-baseline (Follow up 2)

  3. Change in Chronic Pain Self-Efficacy Scale Pain Management Subscale

    Using standard scoring procedures, we will calculate the mean of responses to this subscale's 5 items to yield a total score ranging from 10-100, where higher scores indicate greater self-efficacy for managing chronic pain. Analyses will examine change in pain self-efficacy.

    Time frame: Change in Self-efficacy for pain management from baseline to 34-38 weeks post-baseline (Follow up 3)

  4. Change in Pain Catastrophizing Scale

    Using standard scoring methods, we will sum responses for the 13 items on this scale to yield a score ranging from 0-52, where higher scores indicate greater pain catastrophizing. Analyses will examine change in pain catastrophizing from baseline; change from baseline to post-intervention (follow up 1) will also be examined as a potential mediator of changes in pain severity and interference.

    Time frame: Change in PCS scale scores from baseline to 10-14 weeks post-baseline (Follow up 1)

  5. Change in Pain Catastrophizing Scale

    Using standard scoring methods, we will sum responses for the 13 items on this scale to yield a score ranging from 0-52, where higher scores indicate greater pain catastrophizing. Analyses will examine change in pain catastrophizing.

    Time frame: Change in PCS scale scores from baseline to 22-24 weeks post-baseline (Follow up 2)

  6. Change in Pain Catastrophizing Scale

    Using standard scoring methods, we will sum responses for the 13 items on this scale to yield a score ranging from 0-52, where higher scores indicate greater pain catastrophizing. Analyses will examine change in pain catastrophizing.

    Time frame: Change in PCS scale scores from baseline to 34-38 weeks post-baseline (Follow up 3)

  7. Change in Patient Reported Outcomes Measurement Information System (PROMIS) 8-item Sleep Disturbance

    Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep disturbance. Analyses will examine group differences in change in sleep disturbance.

    Time frame: Change in PROMIS sleep disturbance scores from baseline to 10-14 weeks post-baseline (Follow up 1)

  8. Change in Patient Reported Outcomes Measurement Information System (PROMIS) 8-item Sleep Disturbance

    Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep disturbance. Analyses will examine group differences in change in sleep disturbance.

    Time frame: Change in PROMIS sleep disturbance scores from baseline to 22-26 weeks post-baseline (Follow up 2)

  9. Change in Patient Reported Outcomes Measurement Information System (PROMIS) 8-item Sleep Disturbance

    Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep disturbance. Analyses will examine group differences in change in sleep disturbance.

    Time frame: Change in PROMIS sleep disturbance scores from baseline to 34-38 weeks post-baseline (Follow up 3)

  10. Change in PROMIS 8-item Sleep-Related Impairment

    Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep-related impairment. Analyses will examine group differences in change in sleep-related impairment.

    Time frame: Change in PROMIS sleep-related impairment scores from baseline to 10-14 weeks post-baseline (Follow up 1)

  11. Change in PROMIS 8-item Sleep-Related Impairment

    Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep-related impairment. Analyses will examine group differences in change in sleep-related impairment.

    Time frame: Change in PROMIS sleep-related impairment scores from baseline to 22-26 weeks post-baseline (Follow up 2)

  12. Change in PROMIS 8-item Sleep-Related Impairment

    Using standard scoring procedures for this scale, we will sum responses and calculate T-scores that rescale raw scores into a standardized score with a mean of 50 and a standard deviation of 10; higher scores indicate greater sleep-related impairment. Analyses will examine group differences in change in sleep-related impairment.

    Time frame: Change in PROMIS sleep-related impairment scores from baseline to 34-38 weeks post-baseline (Follow up 3)

  13. Change in Menopause Specific quality of Life Questionnaire (MENQOL) Vasomotor Subscale

    Using standard scoring procedures for the 3-item vasomotor subscale, we will calculate the mean of responses to yield a score ranging from 1 to 8; higher scores indicated higher vasomotor symptoms. Analyses will examine change in vasomotor symptoms.

    Time frame: Change in MENQOL scores from baseline to 10-14 weeks post-baseline (Follow up 1)

  14. Change in Menopause Specific quality of Life Questionnaire (MENQOL) Vasomotor Subscale

    Using standard scoring procedures for the 3-item vasomotor subscale, we will calculate the mean of responses to yield a score ranging from 1 to 8; higher scores indicated higher vasomotor symptoms. Analyses will examine change in vasomotor symptoms.

    Time frame: Change in MENQOL scores from baseline to 22-26 weeks post-baseline (Follow up 2)

  15. Change in Menopause Specific quality of Life Questionnaire (MENQOL) Vasomotor Subscale

    Using standard scoring procedures for the 3-item vasomotor subscale, we will calculate the mean of responses to yield a score ranging from 1 to 8; higher scores indicated higher vasomotor symptoms. Analyses will examine change in vasomotor symptoms.

    Time frame: Change in MENQOL scores from baseline to 34-38 weeks post-baseline (Follow up 3)

07

Study locations

2 sites
08

References and documents

Publications

  • Hosseinian Z, Lehan A, Powers JM, Melendez A, Fisher HM, Shelby R, Somers T, Keefe F, Paice J, Kimmick G, Burns J, Flores AM, Fox RS, Kaiser K, Farrell D, Westbrook K, Rini C. Web-Based Pain Coping Skills Training (PCST) for Managing Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: Randomized Controlled Trial Protocol. Contemp Clin Trials. 2025 Feb;149:107780. doi: 10.1016/j.cct.2024.107780. Epub 2024 Dec 18. PubMed 39706331 ↗

Individual participant data

Plan to share: No — Data will be shared according to the most recent NIH guidelines for sharing research data (https://grants.nih.gov/grants/policy/data_sharing/). Findings will be disseminated through presentations at national scientific meetings and peer-reviewed manuscripts. We will make our data available for review and/or research to qualified individuals after the main findings from the final dataset are accepted for publication. Individuals requesting data will be asked to describe their goals, data needs and planned analyses including statistical power. Requests will be reviewed by a Data Access Committee made up of the project's key personnel. This committee will evaluate scientific validity, statistical power, overlap with other analyses/publications, and ethical aspects of the proposed use of the data. We will protect the rights and privacy of our study participants by de-identifying the data and taking any other steps necessary to eliminate potential deductive disclosure.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Nov 2026, 46 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 46 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2023
First posted
Jan 27, 2023
StartActual
Jan 19, 2023
Primary completionEst.
Nov 30, 2026
CompletionEst.
May 1, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05703178
Responsible party
Christine Rini, PhD (Professor, Northwestern University) — Principal investigator
First posted
Jan 27, 2023
Start date
Jan 19, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion